Congress is relentlessly buying UnitedHealth stock despite $40% drop; What's the catch?

UnitedHealth Group (UNH) shares have plummeted 40% year-to-date in 2025 amid significant corporate challenges, including an abrupt CEO resignation, suspended full-year guidance due to rising medical costs, and a reported DOJ criminal probe into its Medicare Advantage billing. Despite this turmoil, numerous U.S. Congress members have actively purchased UNH stock, with 19 reported trades across both parties, many of which are now significantly underwater. This unusual buying activity during a period of acute distress prompts questions for investors regarding whether these represent high-conviction plays or potential value traps.

Analysis

UnitedHealth Group (UNH) is facing a confluence of severe operational and governance crises, reflected in a 40% year-to-date stock price decline. The core issues stem from the abrupt resignation of CEO Andrew Witty on May 13, followed by the suspension of full-year 2025 guidance due to rising medical costs and utilization in its pivotal Medicare Advantage segment. These events signal significant margin pressure and a lack of near-term visibility. The situation was further exacerbated by a Wall Street Journal report of a Department of Justice criminal probe into the company's billing practices, a claim UNH has refuted. In a stark contrast to these bearish fundamentals, U.S. Congress members from both parties have engaged in notable buying activity, with 19 transactions recorded in 2025. This buying peaked during the period of maximum distress, and many of these positions are currently held at significant losses, ranging from -10% to -65%. This unusual, contrarian activity from lawmakers, juxtaposed against severe negative catalysts, creates a complex dynamic for investors, pitting deep fundamental uncertainty against potential high-conviction political insider sentiment.

Key Decisions for Investors

• Given the suspended guidance, CEO turnover, and a potential DOJ investigation, investors should recognize the significant near-term headline risk and fundamental uncertainty surrounding UNH.
• The sustained, bipartisan buying by Congress members, despite immediate paper losses, serves as a notable contrarian signal that may warrant further monitoring for those with a high risk tolerance and long-term horizon.
• Key catalysts to watch before adjusting a position include any official clarification on the DOJ probe, the reinstatement of financial guidance, and the strategic vision articulated by the returning former CEO.
• While the 40% stock decline presents a potentially attractive valuation, this must be carefully weighed against clear evidence of deteriorating fundamentals, specifically the margin pressure in the critical Medicare Advantage business.